Skip to content
    Clinical Trials

    Etentamig (Investigational) in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

    Baljevic et alBlood

    Etentamig (Investigational) in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
    Long-term pooled efficacy and safety data from the ongoing open-label phase 1 (NCT03933735) and phase 1b Arm A (NCT05650632) trials evaluated etentamig, an investigational B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager, in adult patients with triple-class-exposed relapsed/refractory multiple myeloma who had received at least 3 prior lines of therapy. Etentamig is engineered with a low-affinity CD3-binding domain intended to potentially reduce cytokine release syndrome (CRS) and infections, a high-avidity bivalent BCMA-binding domain, and retained FcRn binding to support extended monthly (Q4W) dosing following a single step-up dose (SUD).
    The pooled cohort comprised 146 patients with a median age of 68 years and a median of 4 prior lines of therapy (range, 3–23). In the phase 1 trial, patients received either 60 mg Q4W or 40 mg every 3 weeks (Q3W); in phase 1b Arm A, administration consisted of an SUD on Day 1 followed by 60 mg Q4W starting on Day 4. Across a median follow-up of 13 months (range, 1–48), objective responses occurred in 66% of patients, and 54% achieved a very good partial response or better. Median duration of response and median progression-free survival were not reached.
    The safety analysis suggested a manageable profile across the cohort, with Grade 3/4 neutropenia reported in 38% of patients and Grade 3/4 infections in 23%. In phase 1b Arm A (n=23), who received modified dexamethasone premedication alongside one SUD, the overall incidence of CRS was 30% (26% Grade 1; 4% Grade 2), with a median onset of 22.3 hours (range, 5.5–29.6) and a median duration to resolution of 20.7 hours (range, 1.8–131.7). The authors noted that the molecular architecture of etentamig may be associated with the observed efficacy, tolerability, and feasibility of extended dosing intervals.

    Key Takeaways

    • In 146 patients with triple-class-exposed relapsed/refractory multiple myeloma, etentamig yielded an objective response rate of 66% and a very good partial response or better rate of 54%, with both median duration of response and median progression-free survival not reached at a median follow-up of 13 months.
    • Pooled safety findings showed Grade 3/4 neutropenia in 38% of patients and Grade 3/4 infections in 23%, with cytokine release syndrome occurring in 30% of phase 1b Arm A patients (26% Grade 1; 4% Grade 2; no Grade ≥3) following modified dexamethasone premedication and a single step-up dose.